Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;17(35):4849-4860.
doi: 10.2217/fon-2021-0778. Epub 2021 Sep 23.

Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma

Rahul Banerjee  1 , Mimi Lo  2 , Thomas G Martin 3rd  1
Affiliations
Review

Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma

Rahul Banerjee et al. Future Oncol. 2021 Dec.

Abstract

The treatment of relapsed multiple myeloma remains challenging. Based on interim data from the randomized Phase III IKEMA study demonstrating a progression-free survival benefit with a combination of isatuximab (Isa, a CD38-targeted monoclonal antibody) and carfilzomib/dexamethasone (Kd) versus Kd alone, Isa-Kd recently received regulatory approval in the USA and Europe for patients with multiple myeloma who have received at least one prior line of therapy (in the USA, up to three prior lines). In this review we discuss the rationale and clinical trial experience to date with Isa-Kd. Although final IKEMA results are pending, Isa-Kd has emerged as an effective and tolerable therapy for patients with relapsed multiple myeloma. Given the growing number of antibody-containing triplet regimens in this setting, potential niches and limitations for Isa-Kd are also discussed.

Keywords: carfilzomib; isatuximab; monoclonal antibodies; multiple myeloma.

Plain language summary

Lay abstract For patients with multiple myeloma, navigating cancer relapses can be difficult. The combination of isatuximab, carfilzomib and dexamethasone (Isa-Kd), which was studied in the large ongoing IKEMA study, has recently been approved by government authorities in both the USA and Europe for treating multiple myeloma that has relapsed after initial therapy. Isatuximab is a drug that attacks the CD38 protein on myeloma cancer cells, while carfilzomib is a drug that prevents myeloma cancer cells from properly using and reusing proteins. Dexamethasone is a corticosteroid that has been shown to improve how well other antimyeloma drugs work. In this review, we discuss potential strengths and weaknesses of the Isa-Kd combination for patients with multiple myeloma that has relapsed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources